» Articles » PMID: 20086250

IGF-1 Suppresses Bim Expression in Multiple Myeloma Via Epigenetic and Posttranslational Mechanisms

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2010 Jan 21
PMID 20086250
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin-like growth factor-1 (IGF-1) is an important growth and survival factor in multiple myeloma (MM). Here, we demonstrate that IGF-1 induces significant down-regulation of the proapoptotic BH3-only protein Bim in MM cells. Reduced Bim levels by RNA interference (RNAi) protected cells from drug-induced cell death. The IGF-1-mediated down-regulation of Bim was the result of (1) reduced transcription by activation of the Akt pathway and inactivation of the transcription factor FoxO3a, (2) increased proteasome-mediated degradation of the Bim extra-long protein by activation of the mitogen-activated protein kinase pathway, and (3) epigenetic regulation of both the Bim and the FoxO3a promoter. Treatment of cells with the histone deacetylase inhibitor LBH589 resulted in a clear up-regulation in the expression of Bim. Furthermore, the methylation inhibitor 5-aza-2'deoxycytidine (decitabine) significantly increased the effects of LBH589. On IGF-1 treatment, the Bim promoter region was found to be unmethylated, whereas chromatin immunoprecipitation analysis of the IGF-1-treated cells showed both a reduced histone H3 tail Lys9 (H3K9) acetylation and an increased H3K9 dimethylation, which contributed actively to its silencing. These data identify a new mechanism in the IGF-1-dependent survival of MM cells and emphasize the need for IGF-1-targeted drug therapy.

Citing Articles

Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy.

Nwabo Kamdje A, Dongmo Fogang H, Mimche P Front Mol Med. 2024; 4:1426454.

PMID: 39308891 PMC: 11412843. DOI: 10.3389/fmmed.2024.1426454.


Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.

Yoshimura A, Horinaka M, Yaoi T, Ono H, Itoh K, Yamada T Br J Cancer. 2024; 131(2):361-371.

PMID: 38822146 PMC: 11263561. DOI: 10.1038/s41416-024-02727-2.


Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.

Fan R, Satilmis H, Vandewalle N, Verheye E, de Bruyne E, Menu E Blood Cancer J. 2023; 13(1):188.

PMID: 38110349 PMC: 10728073. DOI: 10.1038/s41408-023-00962-z.


Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.

Bahar M, Kim H, Kim D Signal Transduct Target Ther. 2023; 8(1):455.

PMID: 38105263 PMC: 10725898. DOI: 10.1038/s41392-023-01705-z.


Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition.

To K, Chow J, Cheung K, Cho W ACS Pharmacol Transl Sci. 2023; 6(10):1531-1543.

PMID: 37854628 PMC: 10580381. DOI: 10.1021/acsptsci.3c00202.